These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1823 related articles for article (PubMed ID: 30753825)

  • 61. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 64. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
    Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Are we over-treating with checkpoint inhibitors?
    Danson S; Hook J; Marshall H; Smith A; Bell S; Rodwell S; Corrie P
    Br J Cancer; 2019 Oct; 121(8):629-630. PubMed ID: 31527686
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
    Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
    Riley JL
    N Engl J Med; 2013 Jul; 369(2):187-9. PubMed ID: 23724866
    [No Abstract]   [Full Text] [Related]  

  • 73. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
    Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
    Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mechanisms of Resistance to Immune Checkpoint Blockade.
    Liu D; Jenkins RW; Sullivan RJ
    Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Shoushtari AN; Munhoz RR; Kuk D; Ott PA; Johnson DB; Tsai KK; Rapisuwon S; Eroglu Z; Sullivan RJ; Luke JJ; Gangadhar TC; Salama AK; Clark V; Burias C; Puzanov I; Atkins MB; Algazi AP; Ribas A; Wolchok JD; Postow MA
    Cancer; 2016 Nov; 122(21):3354-3362. PubMed ID: 27533633
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
    Cybulska-Stopa B; Rogala P; Czarnecka AM; Ługowska I; Teterycz P; Galus Ł; Rajczykowski M; Dawidowska A; Piejko K; Suwiński R; Mackiewicz J; Rutkowski P
    Adv Med Sci; 2020 Sep; 65(2):316-323. PubMed ID: 32554313
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 79. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 92.